JP2006507220A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006507220A5 JP2006507220A5 JP2003587783A JP2003587783A JP2006507220A5 JP 2006507220 A5 JP2006507220 A5 JP 2006507220A5 JP 2003587783 A JP2003587783 A JP 2003587783A JP 2003587783 A JP2003587783 A JP 2003587783A JP 2006507220 A5 JP2006507220 A5 JP 2006507220A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition
- disease
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 18
- 208000010877 cognitive disease Diseases 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 230000004770 neurodegeneration Effects 0.000 claims 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 4
- 230000001149 cognitive effect Effects 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 1
- 150000001602 bicycloalkyls Chemical group 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37609302P | 2002-04-26 | 2002-04-26 | |
| PCT/US2003/012694 WO2003091220A1 (en) | 2002-04-26 | 2003-04-24 | Muscarinic antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009285736A Division JP2010059213A (ja) | 2002-04-26 | 2009-12-16 | ムスカリン性アンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006507220A JP2006507220A (ja) | 2006-03-02 |
| JP2006507220A5 true JP2006507220A5 (enExample) | 2006-05-25 |
| JP4527408B2 JP4527408B2 (ja) | 2010-08-18 |
Family
ID=29270760
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003587783A Expired - Fee Related JP4527408B2 (ja) | 2002-04-26 | 2003-04-24 | ムスカリン性アンタゴニスト |
| JP2009285736A Withdrawn JP2010059213A (ja) | 2002-04-26 | 2009-12-16 | ムスカリン性アンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009285736A Withdrawn JP2010059213A (ja) | 2002-04-26 | 2009-12-16 | ムスカリン性アンタゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6890936B2 (enExample) |
| EP (1) | EP1499596B1 (enExample) |
| JP (2) | JP4527408B2 (enExample) |
| CN (1) | CN1649845A (enExample) |
| AT (1) | ATE413388T1 (enExample) |
| AU (1) | AU2003228674A1 (enExample) |
| CA (1) | CA2484217A1 (enExample) |
| DE (1) | DE60324544D1 (enExample) |
| ES (1) | ES2315494T3 (enExample) |
| MX (1) | MXPA04010552A (enExample) |
| WO (1) | WO2003091220A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101880277A (zh) | 2003-04-24 | 2010-11-10 | 因塞特公司 | 作为金属蛋白酶抑制剂的氮杂螺烷衍生物 |
| CN101044134A (zh) | 2004-09-20 | 2007-09-26 | 塔加西普特公司 | 具有烟碱性胆碱能受体活性的氮杂螺烯和氮杂螺烷化合物 |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
| AU2007299726A1 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
| US20080108574A1 (en) * | 2006-09-27 | 2008-05-08 | Braincells, Inc. | Melanocortin receptor mediated modulation of neurogenesis |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| EP2091948B1 (en) | 2006-11-30 | 2012-04-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
| CA2679446C (en) | 2007-03-01 | 2016-05-17 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| TW200902007A (en) * | 2007-05-25 | 2009-01-16 | Astrazeneca Ab | Spirocyclopropyl piperidine derivatives |
| US20100130477A1 (en) * | 2008-11-25 | 2010-05-27 | Astrazeneca Ab | Spirocyclobutyl Piperidine Derivatives |
| BR112012008346B1 (pt) | 2009-09-11 | 2021-12-21 | Vivoryon Therapeutics N.V. | Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica |
| EP2533645B1 (en) | 2010-02-09 | 2016-07-27 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| US20110281853A1 (en) | 2010-05-12 | 2011-11-17 | Rishi Arora | Compositions and methods for treating or preventing atrial fibrillation |
| WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| EP2968220B1 (en) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| SG11201702982UA (en) | 2014-10-31 | 2017-05-30 | Indivior Uk Ltd | Dopamine d3 receptor antagonists compounds |
| MX384391B (es) | 2015-05-22 | 2025-03-14 | Agenebio Inc | Composiciones farmacéuticas de levetiracetam de liberación extendida. |
| AU2018300980A1 (en) * | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| US11299481B2 (en) | 2017-10-20 | 2022-04-12 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| EP3732163A4 (en) * | 2017-12-20 | 2021-07-14 | Vanderbilt University | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS |
| TWI767148B (zh) * | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04225953A (ja) * | 1990-05-07 | 1992-08-14 | Shionogi & Co Ltd | スピロ ジベンゾスベラン誘導体 |
| GB9309422D0 (en) * | 1993-05-07 | 1993-06-23 | Res Inst Medicine Chem | Chemical compounds |
| WO1999032489A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| CA2444595A1 (en) * | 2001-04-20 | 2002-10-31 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
-
2003
- 2003-04-24 AU AU2003228674A patent/AU2003228674A1/en not_active Abandoned
- 2003-04-24 ES ES03726436T patent/ES2315494T3/es not_active Expired - Lifetime
- 2003-04-24 MX MXPA04010552A patent/MXPA04010552A/es unknown
- 2003-04-24 CA CA002484217A patent/CA2484217A1/en not_active Abandoned
- 2003-04-24 CN CNA038094436A patent/CN1649845A/zh active Pending
- 2003-04-24 AT AT03726436T patent/ATE413388T1/de not_active IP Right Cessation
- 2003-04-24 EP EP03726436A patent/EP1499596B1/en not_active Expired - Lifetime
- 2003-04-24 DE DE60324544T patent/DE60324544D1/de not_active Expired - Lifetime
- 2003-04-24 JP JP2003587783A patent/JP4527408B2/ja not_active Expired - Fee Related
- 2003-04-24 WO PCT/US2003/012694 patent/WO2003091220A1/en not_active Ceased
- 2003-04-28 US US10/425,376 patent/US6890936B2/en not_active Expired - Fee Related
-
2009
- 2009-12-16 JP JP2009285736A patent/JP2010059213A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006507220A5 (enExample) | ||
| RU2002107975A (ru) | Глюкопиранозилоксипиразольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для их получения | |
| EP1619192A3 (en) | Aryl fused azapolycyclic compounds | |
| DE60219954D1 (de) | Neue Indol-2-on Derivate | |
| GEP20094723B (en) | Tetraazabenzo [e] azulene derivatives and analogs thereof | |
| JP2006503850A5 (enExample) | ||
| JP2009507909A5 (enExample) | ||
| JP2007507494A5 (enExample) | ||
| SE0104334D0 (sv) | Therapeutic agents | |
| MXPA01006474A (es) | Derivados colquinol como agentes perjudiciales vasculares. | |
| JP2009504763A5 (enExample) | ||
| TW200607807A (en) | Macrocyclic beta-secretase inhibitors | |
| JP2005502680A5 (enExample) | ||
| CN107105660A (zh) | 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法 | |
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JP2003519228A5 (enExample) | ||
| ATE367387T1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
| RU2003134629A (ru) | Соединения цефема | |
| EP2202222A3 (en) | Indene derivatives, their preparation and use as medicaments | |
| KR100292928B1 (ko) | 치환된헥사하이드로벤조페난트리딘 | |
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| KR102425709B1 (ko) | Dp 길항제 | |
| JP2003509494A5 (enExample) | ||
| JP2006500315A (ja) | 糖尿病状態に用いるヒスタミン−３受容体リガンド | |
| RU2004111787A (ru) | Ретиноидные агонисты (1), производные алкилмочевины |